(ANVS) |
| 0 (0%) 09-16 04:18 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.91 |
| Resistance 1: | 1.60 |
| Pivot price: | 1.47 |
| Support 1: | 1.10 |
| Support 2: | 0.91 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -1.750 |
| Book Value | -0.100 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -142.4 |
| Return on Equity (ttm) | -703.7 |
Company news
Tue, 08 Sep 2026
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Wed, 02 Sep 2026
ANVS: Alzheimer's phase III top-line data due in March; funding needed to reach NDA and commercialization - TradingView
Tue, 25 Aug 2026
Annovis says Alzheimer’s trial is fully enrolled, with data expected in 2027 - Stock Titan
Fri, 14 Aug 2026
Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls | ANVS Stock News - Quiver Quantitative
Wed, 08 Jul 2026
$ANVS stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
Tue, 07 Jul 2026
Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease - moomoo.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
